GLIOMATCH is a Horizon Europe project dedicated to pioneering targeted treatments for brain cancer. Led by KU Leuven, the project brings together more than a dozen partners from ten EU member states to advance personalised medicine for one of the most lethal cancer types. In line with Europe’s Beating Cancer Plan, GLIOMATCH contributes to the EU Cancer Mission’s objectives through the ‘Understanding (Tumour-Host) Interactions’ Cluster. By making technology for customised treatments accessible to clinicians, GLIOMATCH aims to relieve the burden brain tumours place on patients, families, and healthcare systems across Europe.
Find out more about the GLIOMATCH project by watching our explainer video. In the video, Prof. Frederik De Smet (KUL), GLIOMATCH project coordinator, breaks down the project’s objectives, innovation, and overall structure.
On World Cancer Day 2026, GLIOMATCH highlights the importance of placing patient perspectives at the heart of cancer research, particularly for glioblastoma, one of the most aggressive and difficult-to-treat brain tumours.
From 25 to 27 March 2025, the GLIOMATCH consortium convened in Düsseldorf, Germany, for its third consortium meeting. The meeting was held in-person and hosted by the partner University of Düsseldorf (UDUS). Over 40 experts from across Europe gathered to assess progress of the past year and plan the next phase of the GLIOMATCH project.
On the 10th anniversary of the International Day of Women and Girls in Science, GLIOMATCH celebrates the women driving our research and our commitment to gender balance in science and leadership.
